Cancers. 2021 Jun 11;13(12):2938. doi: 10.3390/cancers13122938 Q24.42025
PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
PSMA表达可预测转移性去势抵抗性前列腺癌患者在177Lu-PSMA-617放射配体治疗下的早期生物标志物反应 翻译改进
Liam Widjaja 1, Rudolf A Werner 1, Tobias L Ross 1, Frank M Bengel 1, Thorsten Derlin 1
作者单位 +展开
作者单位
DOI: 10.3390/cancers13122938 PMID: 34208246
摘要 Ai翻译
相关内容
-
Increased PSMA Expression in 177 Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide : A Potential Game-Changer
接受PSMA放射配体治疗和enzalutamide的转移性去势抵抗性前列腺癌患者的177Lu-PSMA-617扫描中PSMA表达增加：可能改变游戏规则的现象
Piyush Aggarwal et al.
Clinical nuclear medicine. 2023 May 1;48(5):411-413.
-
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
开发用于治疗PSMA表达中等水平的前列腺癌的[177Lu]Lu-LNC1003放射配体疗法
Xuejun Wen et al.
European journal of nuclear medicine and molecular imaging. 2023 Jul;50(9):2846-2860.
-
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy
分析接受177Lu-PSMA-617放射配体治疗的晚期前列腺癌患者的PSMA表达和预后
Robert Seifert et al.
Theranostics. 2020 Jun 19;10(17):7812-7820.
-
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
低前列腺特异性膜抗原（PSMA）表达的转移性去势抵抗性前列腺癌患者不适合使用177Lu标记的PSMA放射配体治疗的不良结局
Sue Ping Thang et al.
European urology oncology. 2019 Nov;2(6):670-676.
-
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
前列腺癌诊断中病理科医师的潜在合作伙伴——PSMA表达
Sara Bravaccini et al.
Scientific reports. 2018 Mar 9;8(1):4254.
-
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
可逆的表观遗传学改变介导了晚期转移性前列腺癌中PSMA表达的异质性
Erolcan Sayar et al.
JCI insight. 2023 Apr 10;8(7):e162907.
-
EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy
EAU-EANM关于前列腺特异性膜抗原正电子发射断层扫描/X线计算机体层成像在前列腺癌患者中的作用以及有关[177Lu]Lu-PSMA放射配体治疗的共识声明
Stefano Fanti et al.
European urology oncology. 2022 Oct;5(5):530-536.
-
225Ac-PSMA-617 Augmentation After Insufficient Response Under 177Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)
用于治疗mCRPC的225Ac-PSMA-617增强疗法：在177Lu-PSMA-617放射配体治疗不足的情况下进行的疗效和安全性评估（REALITY研究）
Clinical nuclear medicine. 2024 Dec 31.
